GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Cyclically Adjusted PB Ratio

Zydus Lifesciences (BOM:532321) Cyclically Adjusted PB Ratio : 8.21 (As of May. 28, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Cyclically Adjusted PB Ratio?

As of today (2024-05-28), Zydus Lifesciences's current share price is ₹1058.55. Zydus Lifesciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ₹128.88. Zydus Lifesciences's Cyclically Adjusted PB Ratio for today is 8.21.

The historical rank and industry rank for Zydus Lifesciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

BOM:532321' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.61   Med: 5.3   Max: 8.65
Current: 8.35

During the past years, Zydus Lifesciences's highest Cyclically Adjusted PB Ratio was 8.65. The lowest was 3.61. And the median was 5.30.

BOM:532321's Cyclically Adjusted PB Ratio is ranked worse than
91.63% of 693 companies
in the Drug Manufacturers industry
Industry Median: 1.86 vs BOM:532321: 8.35

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Zydus Lifesciences's adjusted book value per share data for the three months ended in Mar. 2024 was ₹197.067. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹128.88 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zydus Lifesciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Zydus Lifesciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Cyclically Adjusted PB Ratio Chart

Zydus Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.41 5.73 3.75 4.45 7.80

Zydus Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.45 - 5.10 - 7.80

Competitive Comparison of Zydus Lifesciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Cyclically Adjusted PB Ratio falls into.



Zydus Lifesciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Zydus Lifesciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1058.55/128.88
=8.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zydus Lifesciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Zydus Lifesciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=197.067/153.0345*153.0345
=197.067

Current CPI (Mar. 2024) = 153.0345.

Zydus Lifesciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 94.103 0.000
201409 38.242 96.780 60.470
201412 0.000 96.780 0.000
201503 44.160 97.163 69.553
201506 0.000 99.841 0.000
201509 48.524 101.753 72.979
201512 0.000 102.901 0.000
201603 55.670 102.518 83.102
201606 0.000 105.961 0.000
201609 62.647 105.961 90.478
201612 0.000 105.196 0.000
201703 67.986 105.196 98.903
201706 0.000 107.109 0.000
201709 74.402 109.021 104.439
201712 0.000 109.404 0.000
201803 85.417 109.786 119.065
201806 0.000 111.317 0.000
201809 87.027 115.142 115.667
201812 0.000 115.142 0.000
201903 101.454 118.202 131.351
201906 0.000 120.880 0.000
201909 100.601 123.175 124.988
201912 0.000 126.235 0.000
202003 101.351 124.705 124.375
202006 0.000 127.000 0.000
202009 114.820 130.118 135.042
202012 0.000 130.889 0.000
202103 126.910 131.771 147.390
202106 0.000 134.084 0.000
202109 158.129 135.847 178.136
202112 0.000 138.161 0.000
202203 166.054 138.822 183.055
202206 0.000 142.347 0.000
202209 164.641 144.661 174.171
202212 0.000 145.763 0.000
202303 173.047 146.865 180.317
202306 0.000 150.280 0.000
202309 185.070 151.492 186.954
202312 0.000 152.924 0.000
202403 197.067 153.035 197.067

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zydus Lifesciences  (BOM:532321) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Zydus Lifesciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences (BOM:532321) Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines